263 related articles for article (PubMed ID: 35257056)
21. Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease.
McMurray JJV; Wheeler DC; Stefánsson BV; Jongs N; Postmus D; Correa-Rotter R; Chertow GM; Greene T; Held C; Hou FF; Mann JFE; Rossing P; Sjöström CD; Toto RD; Langkilde AM; Heerspink HJL;
Circulation; 2021 Feb; 143(5):438-448. PubMed ID: 33186054
[TBL] [Abstract][Full Text] [Related]
22. Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA-CKD Trial.
Chertow GM; Correa-Rotter R; Vart P; Jongs N; McMurray JJV; Rossing P; Langkilde AM; Sjöström CD; Toto RD; Wheeler DC; Heerspink HJL;
J Am Heart Assoc; 2023 May; 12(9):e028739. PubMed ID: 37119064
[TBL] [Abstract][Full Text] [Related]
23. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.
Heerspink HJL; Cherney D; Postmus D; Stefánsson BV; Chertow GM; Dwyer JP; Greene T; Kosiborod M; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Toto RD; Wheeler DC;
Kidney Int; 2022 Jan; 101(1):174-184. PubMed ID: 34560136
[TBL] [Abstract][Full Text] [Related]
24. Mineralocorticoid Receptor Antagonists and Renal Outcomes in Heart Failure Patients with and without Chronic Kidney Disease.
Mavrakanas TA; Giannetti N; Sapir-Pichhadze R; Alam A
Cardiorenal Med; 2020; 10(1):32-41. PubMed ID: 31665724
[TBL] [Abstract][Full Text] [Related]
25. Findings of Sodium-Glucose Cotransporter-2 Inhibitor Kidney Outcome Trials Applied to a Canadian Chronic Kidney Disease Population: A Retrospective Cohort Study.
Yi TW; Atiquzzaman M; Zheng Y; Smyth B; Jardine M; Levin A
Can J Kidney Health Dis; 2022; 9():20543581221145068. PubMed ID: 36578697
[TBL] [Abstract][Full Text] [Related]
26. Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD.
Jongs N; Chertow GM; Greene T; McMurray JJV; Langkilde AM; Correa-Rotter R; Kashihara N; Rossing P; Sjöström CD; Stefánsson BV; Toto RD; Wheeler DC; Heerspink HJL; ;
J Am Soc Nephrol; 2022 Nov; 33(11):2094-2107. PubMed ID: 35977807
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
[TBL] [Abstract][Full Text] [Related]
28. SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia.
Fernandez-Fernandez B; Sarafidis P; Kanbay M; Navarro-González JF; Soler MJ; Górriz JL; Ortiz A
Clin Kidney J; 2020 Oct; 13(5):728-733. PubMed ID: 33123352
[TBL] [Abstract][Full Text] [Related]
29. Steroidal MRA Across the Spectrum of Renal Function: A Pooled Analysis of RCTs.
Ferreira JP; Pitt B; McMurray JJV; Pocock SJ; Solomon SD; Pfeffer MA; Zannad F; Rossignol P
JACC Heart Fail; 2022 Nov; 10(11):842-850. PubMed ID: 36328653
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF.
Jhund PS; Solomon SD; Docherty KF; Heerspink HJL; Anand IS; Böhm M; Chopra V; de Boer RA; Desai AS; Ge J; Kitakaze M; Merkley B; O'Meara E; Shou M; Tereshchenko S; Verma S; Vinh PN; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Bengtsson O; Langkilde AM; Sjöstrand M; McMurray JJV
Circulation; 2021 Jan; 143(4):298-309. PubMed ID: 33040613
[TBL] [Abstract][Full Text] [Related]
31. [The dapagliflozin and prevention of adverse outcomes in chronic kidney disease: results of the DAPA-CKD study].
Batyushin MM
Ter Arkh; 2021 Jun; 93(6):713-723. PubMed ID: 36286839
[TBL] [Abstract][Full Text] [Related]
32. Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria.
Heerspink HJ; Provenzano M; Vart P; Jongs N; Correa-Rotter R; Rossing P; Mark PB; Pecoits-Filho R; McMurray JJ; Langkilde AM; Wheeler DC; Toto RB; Chertow GM
Am Heart J; 2024 Apr; 270():125-135. PubMed ID: 38367893
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
Tsukamoto S; Morita R; Yamada T; Urate S; Azushima K; Uneda K; Kobayashi R; Kanaoka T; Wakui H; Tamura K
Diabetes Res Clin Pract; 2022 Dec; 194():110161. PubMed ID: 36403681
[TBL] [Abstract][Full Text] [Related]
34. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials.
Rossing P; Inzucchi SE; Vart P; Jongs N; Docherty KF; Jhund PS; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; DeMets DL; Bengtsson O; Lindberg M; Langkilde AM; Sjöstrand M; Stefansson BV; Karlsson C; Chertow GM; Hou FF; Correa-Rotter R; Toto RD; Wheeler DC; McMurray JJV; Heerspink HJL;
Lancet Diabetes Endocrinol; 2022 Jan; 10(1):24-34. PubMed ID: 34856173
[TBL] [Abstract][Full Text] [Related]
35. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.
Neuen BL; Oshima M; Agarwal R; Arnott C; Cherney DZ; Edwards R; Langkilde AM; Mahaffey KW; McGuire DK; Neal B; Perkovic V; Pong A; Sabatine MS; Raz I; Toyama T; Wanner C; Wheeler DC; Wiviott SD; Zinman B; Heerspink HJL
Circulation; 2022 May; 145(19):1460-1470. PubMed ID: 35394821
[TBL] [Abstract][Full Text] [Related]
36. Dapagliflozin for the treatment of chronic kidney disease.
Kurata Y; Nangaku M
Expert Rev Endocrinol Metab; 2022 Jul; 17(4):275-291. PubMed ID: 35822873
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions.
Vart P; Correa-Rotter R; Hou FF; Jongs N; Chertow GM; Langkilde AM; McMurray JJV; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Douthat W; Escudero E; Isidto R; Khullar D; Bajaj HS; Wheeler DC; Heerspink HJL
Kidney Int Rep; 2022 Apr; 7(4):699-707. PubMed ID: 35497805
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
[TBL] [Abstract][Full Text] [Related]
39. Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection: An Analysis of the DARE-19 Randomized Controlled Trial.
Heerspink HJL; Furtado RHM; Berwanger O; Koch GG; Martinez F; Mukhtar O; Verma S; Gasparyan SB; Tang F; Windsor SL; de Souza-Dantas VC; Del Sueldo M; Frankel R; Javaheri A; Maldonado RA; Morse C; Mota-Gomes M; Shemin D; Silva OL; Tognon AP; Twahirwa M; Buenconsejo J; Esterline R; Oscarsson J; Ambery P; Langkilde AM; Kosiborod MN
Clin J Am Soc Nephrol; 2022 May; 17(5):643-654. PubMed ID: 35483733
[TBL] [Abstract][Full Text] [Related]
40. Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease.
Mima A
Adv Ther; 2021 May; 38(5):2201-2212. PubMed ID: 33860925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
